This study investigates the effects of an investigational medication in combination with other anti-cancer therapies in participants with multiple myeloma. Multiple myeloma is a type of blood cancer that affects plasma cells in the bone marrow. The purpose of this study is to find the best dose for the investigational medication and to understand its benefits when used with other treatments.
Participants in this study will receive the investigational medication along with other therapies. The study will monitor the participants' response to the treatment, focusing on safety and effectiveness. Participants will undergo various medical assessments and tests to measure the impact of the treatment on their condition.
- Who can participate: Adults with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy can participate. Participants must have measurable disease and a good performance status. Exclusion criteria include active plasma cell leukemia, amyloidosis, recent stem cell transplant, POEMS syndrome, and active uncontrolled infections.
- Study details: Participants will receive an investigational medication in combination with other therapies. A placebo is not used in this study. The study will involve regular assessments to monitor the effects of the treatment.
How understandable was the trial content above?
Hard to understand
Easy to understand